In October 2025, the China Antimicrobial Surveillance Network (CHINET), led by the Institute of Antibiotics at Fudan University’s Huashan Hospital (DOI: 10.1186/s44280-025-00092-0), published its 2024 surveillance report in One Health Advances . The report provides an in-depth analysis of antibiotic resistance trends in China, based on an extensive dataset of 458,271 clinical isolates from 74 hospitals across the country. The results show positive developments in the fight against antibiotic-resistant infections, with a significant reduction in resistance to several important pathogens. However, he also highlights the ongoing challenges, especially related to carbapenem-resistant organisms such as Klebsiella pneumoniae and Acinetobacter baumannii.

The CHINET Report 2024 provides a detailed picture of antibiotic resistance across China, highlighting both progress and ongoing problems. Among the clinical isolates collected, gram-negative bacteria dominated with a share of 71.7% of the total, with E. coli, Klebsiella spp. and Staphylococcus aureus topping the list. Methicillin resistance in Staphylococcus species has decreased slightly, with MRSA resistance falling to 28.4%. Meanwhile, Pseudomonas aeruginosa’s resistance to meropenem and imipenem continued its downward trend after declining for several years. However, Acinetobacter baumannii remains a dangerous opponent, with resistance rates to imipenem and meropenem remaining around 64%. In addition, Klebsiella pneumoniae continued to show high levels of resistance, indicating the need for better management of carbapenem antibiotics and further research on alternative treatment options.

Antimicrobial resistance (AMR) has long been a global health crisis, and China has an important role to play in tracking and mitigating its effects. The China Antimicrobial Surveillance Network (CHINET) has been collecting data for years to understand the evolving patterns of resistance across the country. These efforts are part of a global strategy to combat AMR by monitoring the effectiveness of antibiotics and managing clinical treatment. In light of this growing challenge for China’s healthcare system, the 2024 CHINET report provides valuable insights into both the achievements and the areas that still need urgent attention.

Original Paper:

Antimicrobial resistance profile of clinical isolates from hospitals across China: CHINET 2024 surveillance report | One Health Advances | Full Text

Editor: X-Press Journalistenbüro GbR

Gender Notice. The personal designations used in this text always refer equally to female, male and diverse persons. Double/triple naming and gendered designations are used for better readability. ected.